Updates are available Correction dated 2023-03-22

Article History

Received: 25 May 2022

Revised: 6 October 2022

Accepted: 17 October 2022

First Online: 30 October 2022

Change Date: 22 March 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41375-023-01814-2

Competing interests

: MB reports employment with Genentech. TB reports Mayo Clinic Comprehensive Cancer Center Developmental Fund to conduct research P30 CA015083; and honoraria with Pfizer hematology and Oncology. MB reports research support for unrelated project paid to Novartis. NB served as a consultant or had an advisory role with Medexus Pharmaceuticals, Magenta Therapeutics, CareDx Pharma, Sanofi and CTI BioPharma. VB reports institutional grants or contracts from Abbvie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program; consulting fees to self from Genentech, Rigel, Agios, Incyte, Servier Pharmaceuticals LLC, Omeros, Takeda, Partnership for health analytic research, LLC (which in turn, receives funds from Jazz Pharmaceuticals) and Abbvie; safety monitoring committee member for Protagonist; and drug support (institutional) for a trial from Chimerix. VB reports as member of the American Board of Pediatrics Pediatric Hematology/Oncology subboard; National Leader of Pediatric and AYA oncology disease section with Caris Precision Oncology Alliance. JC reports as a member Data Safety Monitoring Board with Allovir, consulting fees with advisory board membership with Jazz Pharmaceuticals, Pfizer, and Amgen; and stocks with Actinium Pharmaceuticals, Bluebird Bio/2Seventy, Dynavax Technologies, aTyr Pharma, Gamida Cell, Miragen Therapeutics, Mustang Bio, Novavax, Ovid Therapeutics, Sorrento Therapeutics, TG Therapeutics, Vaxart, and Veru. RPG reports consulting fees with Ascentage Pharma Group, BeiGene Ltd., Kite Pharma, Inc., Fusion Pharma LLC, LaJolla NanoMedical, Inc., Mingsight Pharma, Inc., Prolacta Bioscience, Inc., CStone Pharmaceuticals. Board participation on FFF Enterprises, Azca, Inc., RakFond Foundation, Antegene Biotech LLC, Stem Rad LTD; and stock or stock options with Bristol Myers. SG reports participation on advisory board with Astellas, Daiichi Sankyo, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca, and Kite Pharma. MRGr reports consulting fees and/or advisory board with Abbvie, Agios/Servier, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Gilead, Incyte, Invitae, Karius, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Sierra Oncology, and Stemline; stock ownership in Medtronic; medical writing with Incyte, Amgen, Jazz, Janssen, Genentech/Roche; and support with Incyte, Genetech/Roche, Janssen. Shahrukh Hashmi reports honorarium for educational talks (all non-promotional, majority on “quality of life” or “survivorship”) in CME accredited educational seminars/conferences. This is over the past 10 years: Pfizer, Novartis, Gilead, Sanofi, Therakos, Janssen, MSD; Relationships: No financial but only volunteer: ASTCT, WBMT, CIBMTR. GH reports grants or contracts from Incyte, Acerta/Astra Zeneca, Takeda, Jazz Pharmaceuticals, and Pharmacyclics; consulting fees from Incyte, Morphosys, Alexio n Pharmaceutcials, Karyopharm, Seattle Genetics, Janssen; participation on a Data Safety Monitoring Board or Advisory Board with Rapa Therapauetics, serves as Vice President, Kentucky Society for Clinical Oncology; Axim Biotechnologies, GW Pharmaceuticals, Cardinal Health, Clovis Oncology, Pfizer, Cellectis, CVS Health, Bluebird Bio, Biogen, Charlottes Webb, AImmune Therapeutics Inc, Medical PPTYS TR Inc, Caretrust Reit Inc, Moderna Therapeutics, Zoom. MK-D reports consulting fees with Darrchi Sankyo. HML reports honoraria for consulting fees from Jazz Pharmaceuticals, CSL Behring, Partner Therapeutics, Actinium, Pluristem, Seattle Genetics; payment or honoraria from speakers’ bureau with Jazz Pharmaceuticals, Seattle Genetics, AstraZeneca; travel reimbursement from Jazz Pharmaceuticals and Seattle Genetics; honoraria for participation on a Data Safety Monitoring Board or Advisory Board with BMS-Celgene and Biosight; and stock options with Partner Therapeutics. DM reports honoraria for AstraZeneca; advisory board for Morphosys and Seagen; and research funding with Genentech, ADC therapeutics, and Karyopharm. AS is the St. Jude Children’s Research Hospital site principal investigator of clinical trials sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287) and by Novartis (NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to AS’s institution. AS has received consultant fee from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. None of these are related to the work presented in this manuscript. Kirsten Williams reports grants for immunotherapy in AML unrelated to current project with Leukemia Lymphoma Society; payment for educational seminar in lung complications of HCT with ASH; ASTCT board of directors meeting; ASH for educational seminar; patents pending for MRD test for AML and ALL unrelated to this work; and leadership roles with ASTCT, CIBMTR, and PTCTC. CH reports the National Heart, Lung, and Blood Institute receives research funding for the laboratory of Dr Hourigan from Sellas; and the National Heart, Lung, and Blood Institute receives research funding for the laboratory of Dr Hourigan from the Foundation of the NIH AML MRD Biomarkers Consortium. PK reports participation on advisory board with Kite, Pfizer, and Jazz. Marcos de Lima reports research agreements (no direct payments) with Miltenyi Biotec; payment to Pfizer; and consulting fees from BMS/Pfizer/Incyte.